Antengene Doses First Patient In Pivotal Phase III ATG-022 Gastric Cancer Trial; Stock Up

Antengene Corporation Ltd. (6996.HK), a commercial-stage biotech company, announced Monday that the first patient has been dosed in China in the pivotal Phase III CLINCH-3 study evaluating ATG-022, a CLDN18.